Thomas Andrew Crockett - 02 Sep 2022 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role: CEO, Director
Signature: /s/ Benjamin L. Palleiko, Attorney-in-Fact
Issuer symbol: KALV
Transactions as of: 02 Sep 2022
Net transactions value: -$22,458
Form type: 4
Filing time: 07 Sep 2022, 16:50:55 UTC
Previous filing: 19 Aug 2022
Next filing: 21 Nov 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KALV	Common Stock	Gift	$0	-6,500	-5.5%	$0.000000	112,178	02 Jul 2022	Direct
transaction	KALV	Common Stock	Sale	$22,458	-1,320	-1.2%	$17.01	110,858	02 Sep 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

Content

The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.